Skip to main
We’re doing some system maintenance
  1. Home
  2. Stocks
  3. Albireo Pharma
ALBO

Buy Albireo Pharma (ALBO) Stock

ALBO
See ALBO stock price and Buy/Sell Albireo Pharma with any amount of money. Discuss news and analyst's price prediction with the investor community. Enter your cell phone number to get started.
ALBO

Albireo Pharma (ALBO)

About Albireo Pharma (ALBO)

Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is h...Read more
Market Cap
$546.57M
1 Year High
$37.86
Volume
93.84k
1 Year Low
$20.30
Price to Earnings Ratio
Open
$27.96
Dividend Rate
High
$29.01
Dividend Yield
Low
$27.82

Community

People who own or watch ALBO stock

Albireo Pharma Stock News

Albireo Pharma stock rating

What analysts recommend for ALBO stock, on a scale from 1 (buy) to 5 (sell).
Buy
Sell
1.2

Albireo Pharma price target

What analysts think ALBO will be worth
Low $20.30
High $73.33
Current $28.20
Target $73.33

Events

List of events that could affect ALBO stock.
01Mar

Earnings data Q4 2021

16May

Earnings data Q1 2022

Albireo Pharma earnings

The value each share was expected to gain vs. the value that each share actually gained
2.9
1.26
-0.38
-2.03
Q3 2021
Q4 2021
Q1 2022
Q2 2022

Expected EPS
Q2 2022
-$1.93
Actual EPS
Q2 2022

Buy Albireo Pharma (ALBO) Stock

ALBO
See ALBO stock price and Buy/Sell Albireo Pharma with any amount of money. Discuss news and analyst's price prediction with the investor community. Enter your cell phone number to get started.

Community

People who own or watch ALBO stock
  • GuNzAbLaZiNg avatar
  • svrdeen avatar
  • KxngAb avatar
  • LightKemist avatar
  • chelly728 avatar
Check the background of this firm on FINRA’s BrokerCheck.

© Copyright 2022 Public Holdings, Inc. All Rights Reserved.

Securities are offered to self-directed customers by Open to the Public Investing, Inc. (“Open to the Public Investing”), a registered broker-dealer and member of FINRA & SIPC. Additional information about your broker can be found by clicking here. Open to Public Investing is a wholly-owned subsidiary of Public Holdings Inc. (“Public Holdings”). This is not an offer, solicitation of an offer or advice to buy or sell securities, or open a brokerage account in any jurisdiction where Open to the Public Investing is not registered. Securities products offered by Open to the Public Investing are not FDIC insured.

Cryptocurrency trading is provided by Apex Crypto LLC (“Apex Crypto”). Apex Crypto is not a registered broker-dealer or FINRA member and is not affiliated with Public Holdings or any of its subsidiaries. Cryptocurrencies are not securities and your cryptocurrency holdings are not FDIC or SIPC insured. Crypto trading involves a substantial risk of loss as there is significant volatility in the price of cryptocurrencies.

Commission-free trading of stocks and ETFs refers to $0 commissions for Open to the Public Investing self-directed individual cash brokerage accounts that trade the U.S. listed securities electronically. Keep in mind, that other fees such as regulatory fees, Premium subscription fees, wire transfer fees, and paper statement fees may apply to your brokerage account. Please see Open to the Public Investing’s Fee Schedule to learn more.

All investments involve the risk of loss and the past performance of a security or a financial product does not guarantee future results or returns.